Abliva AB publishes 2021 Annual report

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version of the Annual report for 2021 is now available on the company’s website, www.abliva.com.

In regard to the Auditor’s disclosure regarding significant uncertainties regarding the assumptions of continued operations, please see the Auditor’s report (page 60-64). Company comments may be found in the CEO comment (page 4) and Administration Report (page 17).